WuXi PharmaTech, Inc. has reached an agreement with Johnson & Johnson Pharmaceutical R&D, Division of Janssen Pharmaceutica, N.V. (J&JPRD) to expand its pharmaceutical R&D services collaboration. In addition to providing discovery chemistry services WuXi, will now also provide research services in the area of discovery biology, chemical and analytical development services, formulation, and preclinical and bioanalytical services, under the new agreement.
Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech, said, "We are very pleased to expand our partnership with J&JPRD. This agreement leverages WuXi's strong R&D capabilities from early stage discovery to commercial production to deliver reliable, high quality and cost-efficient services to J&JPRD. Our partnership demonstrates the strength of our innovation driven and fully integrated R&D service platform."